BIOGEN INC. - COMMON STOCK

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

02 أبريل 2024 09:45:41 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

01 أبريل 2024 10:34:07 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

26 مارس 2024 09:50:02 بحسب NetDania Notify

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

06 مارس 2024 07:30:51 بحسب Nasdaq GlobeNewswire

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

04 مارس 2024 16:15:57 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

01 مارس 2024 09:47:17 بحسب NetDania Notify

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

23 فبراير 2024 07:00:26 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

20 فبراير 2024 09:45:15 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

16 فبراير 2024 09:48:44 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

15 فبراير 2024 10:49:57 بحسب NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

14 فبراير 2024 12:24:11 بحسب NetDania Notify

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

12 فبراير 2024 16:06:00 بحسب Nasdaq GlobeNewswire

Biogen to Realign Resources for Alzheimer's Disease Franchise

31 يناير 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

19 ديسمبر 2023 07:30:21 بحسب Nasdaq GlobeNewswire

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

15 ديسمبر 2023 09:05:25 بحسب Nasdaq GlobeNewswire

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

14 ديسمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

Biogen Appoints Monish Patolawala to its Board of Directors

06 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference

25 أكتوبر 2023 17:26:00 بحسب Nasdaq GlobeNewswire

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

25 أكتوبر 2023 10:51:00 بحسب Nasdaq GlobeNewswire

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

19 أكتوبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire